2 results
Approved WMOCompleted
The primary objectives of this study are: * To characterize the effects of 150 mg and 450 mg of AT1001 administered 2 hours before administration of agalsidase on the safety and plasma pharmacokinetics of agalsidase in subjects with Fabry Disease*…
Approved WMOCompleted
Primary:To compare the effectiveness of TRELEGY ELLIPTA with non-ELLIPTA MITT for the impact of COPDon wellbeing and daily life after 24 weeks* treatment. Secondary:To compare the effectiveness of TRELEGY ELLIPTA with non-ELLIPTA MITT on lung…